1. Home
  2. QDEL vs BBNX Comparison

QDEL vs BBNX Comparison

Compare QDEL & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

N/A

Current Price

$10.73

Market Cap

989.5M

Sector

Health Care

ML Signal

N/A

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

N/A

Current Price

$16.33

Market Cap

897.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QDEL
BBNX
Founded
1979
2015
Country
United States
United States
Employees
N/A
423
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
989.5M
897.6M
IPO Year
2022
2025

Fundamental Metrics

Financial Performance
Metric
QDEL
BBNX
Price
$10.73
$16.33
Analyst Decision
Hold
Buy
Analyst Count
3
15
Target Price
$15.00
★ $25.10
AVG Volume (30 Days)
★ 2.2M
1.1M
Earning Date
11-03-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
★ 78.95
EPS
N/A
★ N/A
Revenue
★ $2,730,200,000.00
$100,251,000.00
Revenue This Year
N/A
$25.22
Revenue Next Year
N/A
$47.09
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 53.94
52 Week Low
$9.92
$8.80
52 Week High
$35.58
$32.71

Technical Indicators

Market Signals
Indicator
QDEL
BBNX
Relative Strength Index (RSI) 37.87 45.41
Support Level $10.49 $15.40
Resistance Level $18.15 $18.20
Average True Range (ATR) 1.25 1.62
MACD -0.37 -0.00
Stochastic Oscillator 7.55 25.71

Price Performance

Historical Comparison
QDEL
BBNX

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Share on Social Networks: